JLJiajie Liu

Jiajie Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jiajie Liu has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Lanlan Xiang

    National Material Experimental Teaching Demonstration Center, East China University of Science and Technology, 130 Meilong Road, Shanghai 200237, China

    3 shared publications
  • Xin Teng

    National Material Experimental Teaching Demonstration Center, East China University of Science and Technology, 130 Meilong Road, Shanghai 200237, China

    3 shared publications
  • Hao Wang

    National Material Experimental Teaching Demonstration Center, East China University of Science and Technology, 130 Meilong Road, Shanghai 200237, China

    2 shared publications
  • Ran Li

    National Material Experimental Teaching Demonstration Center, East China University of Science and Technology, 130 Meilong Road, Shanghai 200237, China

    2 shared publications
  • Sisi Yang

    National Material Experimental Teaching Demonstration Center, East China University of Science and Technology, 130 Meilong Road, Shanghai 200237, China

    2 shared publications
  • Wenchen Che

    National Material Experimental Teaching Demonstration Center, East China University of Science and Technology, 130 Meilong Road, Shanghai 200237, China

    2 shared publications

Latest Publications

  • Open Access

    Disulfide-Crosslinked mPEG-PLA-(LA)4 Nanomicelles for Taxane Delivery in Breast Cancer Therapy

    by Yukun Xie, Hao Wang, Lanlan Xiang, Yuchen Shen, Yujie Yang, Jiajie Liu, Xin Teng

    Taxanes represent a crucial class of chemotherapeutic agents clinically employed for the treatment of various malignancies, including breast cancer. Three commonly utilized taxanes—paclitaxel (Taxol), docetaxel (Taxotere), and cabazitaxel—are substantially limited by inherent drawbacks such as poor aqueous solubility, rapid clearance, and non-specific distribution. To enhance their anti-tumor efficacy against breast cancer, an mPEG-PLA-(LA)4 nanomicelle carrier was designed and synthesized in this study for the loading of these three taxanes. These nanomicelles were designed to improve the aqueous compatibility and nanomicelle-mediated delivery of hydrophobic taxanes. In vivo animal experiments were conducted to evaluate the therapeutic effects of the three drug-loaded nanomicelles on subcutaneous human breast cancer MCF-7 xenografts in BALB/c nude mice. The results demonstrated that the injectable paclitaxel, docetaxel, and cabazitaxel micelles exhibited significant inhibitory effects on the MCF-7 xenograft tumors. These findings suggest that mPEG-PLA-(LA)4 DS nanomicelles may serve as a structurally defined and versatile carrier platform for hydrophobic taxane delivery.

  • Open Access

    Docetaxel Micelles: A New Formulation to Diminish Hypersensitivity Reactions

    by Lanlan Xiang, Hao Wang, Jiajie Liu, Yuchen Shen, Yanfen Hu, Wenchen Che, Ran Li, Sisi Yang, Xin Teng

    Background/Objectives: Docetaxel is a potent anti-cancer agent capable of treating various types of cancer. However, it often induces a range of adverse reactions when used with its standard solubilizer, Tween-80, necessitating allergy prophylaxis with dexamethasone prior to administration. To mitigate the risk of allergic reactions, with nanomicelles garnering significant interest due to their enhanced solubility and thermodynamic stability. Methods: In this research, a mPEG-PLA-Lys(Fmoc) micellar carrier with m = 45 and n = 10 was engineered to encapsulate docetaxel, and its self-assembly into micelles was investigated. Additionally, allergic reaction studies were conducted on animals. Results: The findings indicated that the formulation did not cause hemolysis, vascular, or muscle irritation in rabbits, nor did it elicit an allergic response in guinea pigs. Conclusions: These results suggest that nanomicelle-encapsulated docetaxel can diminish the allergic reactions associated with docetaxel injections, offering a novel approach to enhance the therapeutic utility of this outstanding anti-cancer drug.

  • Open Access

    Engineering Docetaxel Micelles for Enhanced Cancer Therapy Through Intermolecular Forces

    by Hao Wang, Feirong Gong, Jiajie Liu, Lanlan Xiang, Yanfen Hu, Wenchen Che, Ran Li, Sisi Yang, Qixin Zhuang, Xin Teng

    Docetaxel has exhibited excellent therapeutic effects in cancer treatment; however, its hydrophobicity, short blood circulation time, and high blood toxicity restrict its clinical application. The use of mPEG-PLA micelles to deliver docetaxel into the body has been verified as an effective approach to enhance its therapeutic efficacy. However, mPEG-PLA micelles are easily disassembled in the bloodstream, which can easily lead to premature drug release. To broaden the application scenarios of mPEG PLA micelles, we utilized the π–π stacking effect as an intermolecular force to design a novel mPEG-PLA-Lys(Fmoc) micelle to enhance the blood stability and permeability of drug-loaded micelles. The result showed that drug-loaded micelles for injection did not alter the tissue selectivity of docetaxel. Intravenous injection of the micelles in nude mice showed better antitumor efficacy than docetaxel injection and tumor recurrence rate is 0%, which is significantly lower than that of docetaxel injection (100%). The micelles designed by this research institute are anticipated to improve the clinical therapeutic effect of docetaxel.